Skip to main content
. 2020 Dec 14;15(12):e0243900. doi: 10.1371/journal.pone.0243900

Fig 4. Kaplan-Meier curves for progression-free survival and overall survival.

Fig 4

(a) and (b); specimens with PD-L1 IR in tumor cells and specimens with PD-L1 IR in immune cells, compared to PD-L1 non-immunoreactive specimens. (c) and (d); comparison between patients with only tumor cells immunoreactive for PD-L1 versus patients with only immune cells immunoreactive for PD-L1. (e) and (f); comparison between patients with tumor cells and/or immune cells immunorective for PD-L1 versus PD-L1 non-immunoreactive patients.